Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Podcasts|October 23, 2026

ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act

In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In the final part of his video interview, Rajneesh Patil of Syneos Health describes an industry trajectory toward a unified intelligence orchestration environment. He argues the future is not one all-knowing model but a trusted system that brings the right evidence to the right human decision at the right time. In that model, study design, execution, and real-world evidence form a continuous feedback loop.
  • A new feature article reports the first multi-site validation of a standardized coordinator satisfaction methodology for eSource-enabled trials, developed by the European Institute for Innovation through Health Data’s eSource Scale-Up Task Force. Across five oncology research centers in North America and Europe, coordinators gave eSource-enabled workflows an overall satisfaction score of 5.79 of 7, with reduced manual entry and electronic data transfer earning strong marks. Perceived reduction in sponsor and monitor queries was the one domain that fell below threshold.
  • The Faster Clinical Trials Act, introduced by Reps. Jake Auchincloss (D-Mass.) and Morgan Griffith (R-Va.), would create an FDA Center for Clinical Trial Innovation to coordinate reusable trial site networks. The bill aims to cut trial costs and enrollment time by at least 30% and could direct as much as $75 million in annual funding to the FDA over five years. Griffith said the bill likely won’t get a vote until next year.

That’s all for today’s ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article